Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of NirmatrelvirNirmatrelvir의 중요한 COVID-19 시험을 가속화하고 알리기 위한 혁신적인 무작위 1상 연구 및 투여 요법 선택Clinical Trial Published on 2022-07-012022-09-11 Journal: Clinical Pharmacology and Therapeutics [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, 치료제, [키워드] accelerated Antiviral antiviral activity Clinical efficacy clinical trial Cohort cohorts Concentration Coronaviridae family coronavirus disease Coronavirus disease 2019 COVID-19 death decrease demonstrated dose Dosing double-blind enhancer evaluated FIVE half-life Hospitalization in vitro inhibitor M pro MAD modeling Nirmatrelvir PF-07321332 pharmacokinetic pharmacokinetic data phase Phase I Placebo placebo-controlled Prevent Quantitative Randomized regimen required Ritonavir Safe Safety safety profile SARS-CoV-2 SARS-CoV-2-infected patient SARS-CoV-2-infected patients seamless Selection Severe acute respiratory syndrome severe disease significantly suggested supported Tolerability Trial Viral load viral replication [DOI] 10.1002/cpt.2603 PMC 바로가기 [Article Type] Clinical Trial
Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variantsCorrespondence Published on 2022-07-012022-10-05 Journal: The Journal of Infection [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] antiviral drug antiviral therapy Aprotinin combination therapy COVID-19 interferon Interferon-beta molnupiravir Nirmatrelvir Remdesivir SARS-CoV-2 SARS-CoV-2 variant [DOI] 10.1016/j.jinf.2022.07.023 [Article Type] Correspondence
PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patientsPF-07321332(니르마트렐비르)는 인간 ENT1 또는 ENT2와 상호작용하지 않음: COVID-19 환자에 대한 시사점Article Published on 2022-07-012022-09-11 Journal: Clinical and translational science [Category] COVID19(2023년), SARS, 치료제, [키워드] acute lung injury antivirals bind Biotransformation Clinical efficacy clinical trials contribute coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient death downregulation drug Efficacy EIDD-1931 Emergency use authorization Endothelial cell ENT ENTs expression Factor FDA food greater hypoxia in vitro inhibitor Interaction investigated lung epithelial Lung injury Lungs metabolite molnupiravir Nirmatrelvir nucleoside nucleoside analog nucleoside analogs pandemic Patient patients with COVID-19 PF-07321332 protease Protease inhibitor reflected Remdesivir Replication repression SARS-CoV-2 Severe acute respiratory syndrome shown substrate substrates the SARS-CoV-2 undergo unlikely US Food and Drug Administration viral replication Viral RNA Virology [DOI] 10.1111/cts.13292 PMC 바로가기 [Article Type] Article
Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal3d-qsar.com 포털을 통해 SARS-CoV-2 주요 프로테아제 억제제에 대한 예측 모델을 개발하기 위한 리간드 기반 및 구조 기반 연구Article Published on 2022-07-012022-09-11 Journal: Journal of computer-aided molecular design [Category] COVID19(2023년), SARS, 치료제, [키워드] 3-D QSAR Analysis applicability approach binding binding energy build calculation Candidates cleavage site co-crystallized Combination COMBINE Compound conservation coronavirus COVID-19 infected patients develop domain drug design Emergency use authorization enzyme EUA feature Final functional protein implicated in viral inhibitor inhibitors joint Ligand ligand-based drug design M pro maturation Metrics Mild-to-moderate Model molecular Nirmatrelvir outcome performed portal Predictive Predictive model promote protease Quantitative reached Replication reported resources robust robustness safety profile SARS-CoV-2 SARS-CoV-2 main protease statistical Structure-activity relationships Structure-based drug design tolerable training set Transcription Treatment U.S. FDA viral replication Virtual screening [DOI] 10.1007/s10822-022-00460-7 PMC 바로가기 [Article Type] Article
SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening고처리량 항바이러스 스크리닝을 위한 SARS-CoV-2 허용 교모세포종 세포주Article Published on 2022-07-012022-09-11 Journal: Antiviral Research [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] ACE2 Administered Antiviral Antiviral screen cathepsin cathepsin B cathepsin L Cell cell line cell lysis cell monolayer cells cellular cellular infection system circulation Complete contagious CPE Cytopathic effect destruction develop effective evidenced expressed expressing fused Glioblastoma implementation infection with SARS-CoV-2 Nirmatrelvir omicron Permissive preclinical study productive viral replication reduction Remdesivir replicate reported required robust SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 variant Spread tested TMPRSS2 U87 cell line. Vaccine variant virus wild-type virus [DOI] 10.1016/j.antiviral.2022.105342 PMC 바로가기 [Article Type] Article
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2SARS-CoV-2 오미크론 하위 계통 BA.1 및 BA.2에 대한 허가된 단일 클론 항체 및 항바이러스제의 효능Article Published on 2022-06-232022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] active against agent Antiviral antiviral drugs assays B.1 bamlanivimab Casirivimab cell-based assay Concentration Cytopathic effect defined drug activity etesevimab Evolution of SARS-CoV-2 Ex vivo Imdevimab individual Lineage lineages Live virus mAb mAbs microneutralization Microneutralization assay molnupiravir monoclonal antibodies monoclonal antibody neutralized Neutralizing activity Nirmatrelvir omicron omicron sublineages remained Remdesivir SARS-CoV-2 SARS-CoV-2 variant sera serum dilution SOT Sotrovimab the SARS-CoV-2 treated wild-type [DOI] 10.3390/v14071374 PMC 바로가기 [Article Type] Article
A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron VariantsACE2 및 TMPRSS2를 발현하는 새로 설계된 A549 세포주는 Delta 및 Omicron 변이체를 포함하여 SARS-CoV-2에 매우 관대합니다.Article Published on 2022-06-232022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료제, [키워드] A549 A549 cell A549 cells ACE2 ACE2 receptor acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 alveolar angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 anti-SARS-CoV-2 Antiviral antiviral drug antiviral drugs antivirals breakthrough infections can be used Cell coronavirus Critical Culture Delta delta and omicron variants drugs EIDD-1931 Express expressed expressing Factor Host human ACE2 human cell identify Including Infection infection with SARS-CoV-2 inhibit SARS-CoV-2 lack LINE nelfinavir New Nirmatrelvir omicron Omicron variants Permissive Remdesivir respiratory Respiratory virus infections SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants Serine severe acute respiratory syndrome Coronavirus Spike protein susceptible the SARS-CoV-2 TMPRSS2 transcript transducing transmembrane serine protease transmembrane serine protease 2 variant Viral viral entry virus infections [DOI] 10.3390/v14071369 PMC 바로가기 [Article Type] Article
COVID-19 update: NIH recommends against ivermectinArticle Published on 2022-06-132023-07-09 Journal: The Medical letter on drugs and therapeutics [Category] COVID19(2023년), [키워드] bebtelovimab COVID-19 Efficacy Ivermectin Lagevrio molnupiravir Nirmatrelvir Paxlovid Remdesivir Ritonavir Veklury
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like ProteaseSARS-CoV-2 파파인 유사 프로테아제 표적화의 진행 상황 및 과제Review Published on 2022-06-092022-09-11 Journal: Journal of medicinal chemistry [Category] Coronavirus, COVID19(2023년), SARS, 변종, 치료제, [키워드] addition Antiviral antiviral drug target approval approved causative agent challenge class cleavage clinic combating COVID-19 pandemic Encouraging highlight Host include inhibitor inhibitors innate immune response knowledge mechanism modulate molnupiravir Nirmatrelvir offer pandemic Papain-like protease pharmacokinetic polymerase polyprotein Progress Protease inhibitor Remdesivir Ritonavir SARS-CoV-2 structure-based design targeting the SARS-CoV-2 U.S. FDA Vaccine variant variants viral infection [DOI] 10.1021/acs.jmedchem.2c00303 PMC 바로가기 [Article Type] Review
Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19낭포성 섬유증 환자를 위한 생리학적 기반 약동학 주도 지침Article Published on 2022-06-012022-09-11 Journal: Clinical Pharmacology and Therapeutics [Category] 변종, [키워드] Administered approach AUC CFTR Combination coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection Cystic cystic fibrosis cytochrome P450 Day decrease dose drug interaction drug-drug interaction elexacaftor eliminated evaluated fibrosis independent information inhibited inhibiting inhibitor inhibitory effect ivacaftor metabolism modeling modulating Nirmatrelvir P450 parameter pharmacokinetic pharmacokinetics physiological predict predicted reduced regimen risk Ritonavir Simulation Taking tezacaftor therapeutic Therapies transmembrane Treatment was performed [DOI] 10.1002/cpt.2585 PMC 바로가기 [Article Type] Article